ABS Arctic Bioscience AS

0.2612USD2.530 NOK · OSL-0.39%Mkt Cap: 7.04M USDP/E: —

Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europ…

Key Statistics

Company
Market Cap7.04M USD
Enterprise Value15.35M USD
Revenue (TTM)5.05M USD
Gross Profit1.14M USD
Net Income (TTM)-4.24M USD
Revenue/Share0.19 USD
Last Price0.2612 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees19
CountryNO
SectorHealthcare
IndustryBiotechnology
ISINNO0010859580
Valuation
P/E (Trailing)—
P/E (Forward)-12.65
PEG—
EV/EBITDA-4.96
EV/Revenue3.04
P/S1.39
P/B0.44
EPS (TTM)-0.15 USD
EPS (Forward)-0.02 USD
52W Range
0.211622% of range0.4336
52W High0.4336 USD
52W Low0.2116 USD
Profitability
Gross Margin27.54%
Oper. Margin-64.61%
EBITDA Margin-61.22%
Profit Margin-102.32%
ROE-23.65%
ROA-14.41%
ROIC-14.14%
ROCE-16.58%
Growth
Revenue Growth33.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.34M USD
CapEx (TTM)2.35M USD
FCF Margin-33.12%
FCF Yield-23.78%
Net Debt8.28M USD
Net Debt/EBITDA-2.68
Net Debt/FCF—
Balance Sheet
Debt/Equity0.37
Current Ratio0.60
Quick Ratio0.21
Book Value/Sh0.60 USD
Cash/Share0.0005 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.26.96M
Float11.99M
Insiders54.98%
Institutions1.38%
Technical
SMA 500.2668 (-2.1%)
SMA 2000.3137 (-16.7%)
Beta1.20
S&P 52W Chg12.00%
Avg Vol (30d)7.01K
Avg Vol (10d)10.35K
Technical Indicators
RSI (14)50.2
MACD0.0107
MACD Signal-0.0159
MACD Hist.+0.0266
BB Upper0.2878 USD
BB Middle0.2554 USD
BB Lower0.2230 USD
BB Width25.40%
ATR (14)0.0268 USD
Vol Ratio (20d)2.11x

About Arctic Bioscience (OSL: ABS)

›

Arctic Bioscience (OSL: ABS) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 19 employees.

The shares were at 2.530 NOK on 20 November 2026, down 24.5% over 52 weeks. Its 52-week range is 2.050 NOK to 4.200 NOK: the price is 39.8% below the high and 23.4% above the low.

Its market capitalisation is 68.20M NOK.

Arctic Bioscience reports return on equity of -23.6%, an operating margin of -64.6% and revenue up 33.9% year over year.

Its debt exceeds its cash by 80.22M NOK, a debt-to-equity ratio of 0.37. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.